蕲蛇酶对急性脑梗死患者血清C反应蛋白及预后的影响  

Influence of acutobin on serum C-reactive protein level and prognosis in acute cerebral infarction patients

作　　者：陈中杰[1] 庄晓荣[1] 郑维红[1] 

机构地区：[1]厦门大学附属中山医院神经内科,厦门361004

出　　处：《海峡药学》2009年第12期19-21,共3页Strait Pharmaceutical Journal

摘　　要：目的研究蕲蛇酶对急性脑梗死患者血清C反应蛋白(CRP)和预后的影响。方法选择125例经CT或MRI确诊的急性脑梗死患者,随机分为治疗组(65例)和对照组(60例),对照组采用常规药物治疗,而治疗组则加用蕲蛇酶治疗,患者均于治疗前及治疗1周、2周、4周后测定血清C-反应蛋白,并根据美国国立卫生研究院卒中量表(NIHSS)进行神经功能评分,用Barthel指数进行日常生活活动(ADL)能力评分。结果治疗后治疗组患者血清C-反应蛋白水平下降,NIHSS评分及ADL能力评分改善,与对照组相比均有显著性差异。结论蕲蛇酶可以显著降低急性脑梗死患者血清CRP水平,改善其神经功能及ADL,对脑梗死病情变化和预后具有重要意义。OBJECTIVE To study the influence of acutobin on serum C-reactive protein （CRP） level and prognosis in acute cerebral infarction patients. METHODS 125 patients with acute cerebral infarction diagnosed by CT/MRI were chosen and divided into two groups randomly. Both the groups were treated with normal method and the treatment group was given acutobin 0.75u by intravenous drip additionally. Serum CRP levels in the two groups were measured by immunoturhidimetry within 72 h after final diagnosis and at one week, two weeks, four weeks after treatment, and nervous function were scored by National Institutes of Health Stroke Scale（NIHSS） and activity of daily living （ADL） by Barthel Index （BI） seperatedly before treatment and after the 1st, 2nd and 4th weeks of treatment. RESULTS Serum CRP levels all increased in the patients.After treatment for one week and two weeks the level decreased obviously in treatment group, while the scores of NIHSS and ADL in treatment group were remarkbly better than in control group after the treatment. All the differences were significant compared with control group. CONCLUSION Acutobin can markedly reduce the serum CRP level in acute cerebral infarction patients and has important significance for the pathogenetic condition change and prognosis of cerebral infarction.

关 键 词：蕲蛇酶 C反应蛋白 预后 急性脑梗死 

分 类 号：R969.4[医药卫生—药理学]